Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 4/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.70 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.70 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.70 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.70 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.70 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.66 |
| ▸ | CYP19A1 known ✓ | P11511 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 6/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.98 |
| ▸ | MEN1 | O00255 | 3/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.98 |
| ▸ | MAPT | P10636 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | SHBG | P04278 | 4/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15445000 | 0.99 | LMNA (1.00) | LMNANR3C1HIF1AMEN1KMT2A | |
| SCHEMBL4877448 | 0.99 | LMNA (1.00) | LMNANR3C1HIF1AMEN1KMT2A | |
| SCHEMBL22761988 | 0.99 | LMNA (1.00) | LMNANR3C1HIF1AMEN1KMT2A | |
| SCHEMBL37494 | 0.99 | LMNA (1.00) | LMNANR3C1HIF1AMEN1KMT2A | |
| SCHEMBL13069287 | 0.99 | LMNA (1.00) | LMNANR3C1HIF1AMEN1KMT2A | |
| SCHEMBL27035399 | 0.99 | LMNA (1.00) | LMNANR3C1HIF1AMEN1KMT2A | |
| Acetic Acid SCHEMBL27624098 | 0.97 | LMNA (0.96) | LMNANR3C1HIF1AMEN1KMT2A | |
| Acetic Acid SCHEMBL609736 | 0.97 | LMNA (0.96) | LMNANR3C1HIF1AMEN1KMT2A | |
| Formic Acid SCHEMBL28467407 | 0.95 | LMNA (0.92) | LMNANR3C1HIF1AMEN1KMT2A | |
| Cyclopropane Carboxylic Acid SCHEMBL27035116 | 0.93 | LMNA (0.88) | LMNANR3C1HIF1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111329865-A | Application of perphenazine in preparation of medicine for treating endometrial cancer | 华东理工大学 | 2020-06-26 | — | — | CN | claimed |
| CN-115297886-A | IL-7R alpha binding compounds | 麦地金公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-113891714-A | Triple therapy to enhance cancer cell killing in low immunogenic cancers | 大连万春布林医药有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-113366023-A | Compositions and methods for stimulating natural killer cells | 弗罗里达中央大学研究基金会 | 2021-09-07 | — | — | CN | disclosed |
| CN-108484571-B | Salts and solid forms of compounds, compositions comprising the same and methods of use thereof | 细胞基因公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-108434149-B | HSPC-sparing therapy for Rb-positive abnormal cell proliferation | G1治疗公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-111700878-A | Drug nanoparticles exhibiting enhanced mucosal transport | 卡拉制药公司 | 2020-09-25 | — | — | CN | disclosed |
| CN-111700880-A | Drug nanoparticles exhibiting enhanced mucosal transport | 卡拉制药公司 | 2020-09-25 | — | — | CN | disclosed |
| CN-111587113-A | Combination therapy for cancer treatment | 科尔沃斯制药股份有限公司 | 2020-08-25 | — | — | CN | disclosed |
| CN-111329865-A | Application of perphenazine in preparation of medicine for treating endometrial cancer | 华东理工大学 | 2020-06-26 | — | — | CN | disclosed |
| CN-110769822-A | N/O-linked degron and degron bodies for protein degradation | C4医药公司 | 2020-02-07 | — | — | CN | disclosed |